Conference Scene: Immune effector mechanisms in tumor immunity

Immunotherapy

Volumn 4, Issue 2, 2012, Pages 141-143

  Sikora, Andrew G ^a   Hailemichael, Yared ^b   Overwijk, Willem W ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BEVACIZUMAB; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; CD40 LIGAND MONOCLONAL ANTIBODY; CD47 ANTIBODY; DEATH RECEPTOR 4; DEATH RECEPTOR 5; FAS ANTIBODY; IPILIMUMAB; RITUXIMAB; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BONE MARROW CELL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RESEARCH; CLINICAL RESEARCH; CONFERENCE PAPER; DATA PROCESSING; HUMAN; IMMUNITY; KILLER CELL; LYMPHOMA; METABOLISM; NONHODGKIN LYMPHOMA; PANCREAS CANCER; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SOLID TUMOR; TRANSLATIONAL RESEARCH; TUMOR IMMUNITY;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; HUMANS; IMMUNITY; IMMUNOTHERAPY; MYELOID CELLS; NEOPLASMS; NEW YORK CITY; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TUMOR ESCAPE;

EID: 84857596771     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.11.177     Document Type: Conference Paper

References (0)